AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26234917 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative assessment using MDVP
Number of subjects: 121
Study 26234917 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessment using MDVP
Number of subjects: 121
Study 24982504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/sirolimus (Tac/Sir)
Number of subjects: 304
Study 24982504 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/methotrexate (Tac/Mtx)
Number of subjects: 304
Study 21672497 — intervention group
Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 199
Study 21672497 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine + A (amantadine 200 mg/d with possible switches to metformin 1,000‐1,500 mg/d and then to zonisamide 100‐400 mg/d)
Number of subjects: 199
Study 21672497 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine + B (metformin 1,000‐1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100‐400 mg/d)
Number of subjects: 199
Study 21672497 — intervention group
Group type: COMPARATOR
Intervention: pooled results of olanzapine + A and olanzapine + B
Number of subjects: 199
Study 21672497 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine + B
Number of subjects: 199
Study 20136825 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 94
Study 20136825 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDara-C)
Number of subjects: 94
Study 18768415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (n = 175)
Number of subjects: 353
Study 18768415 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (n = 178)
Number of subjects: 353
Study 16086806 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group participation
Number of subjects: 20
Study 12881348 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg midazolam
Number of subjects: 32
Study 12881348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10378499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stimulus (10 degrees C to 12 degrees C) for 10 seconds followed by a cold wetpack at the neck for 1 minute.
Number of subjects: 24
Study 10378499 — intervention group
Group type: COMPARATOR
Intervention: Warm stimulus (34 degrees C to 36 degrees C) for the same duration.
Number of subjects: 24
Study 8767942 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 20
Study 8767942 — intervention group
Group type: COMPARATOR
Intervention: Traditional open surgery
Number of subjects: 20
Study 1984813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA) 50 to 100 mg daily
Number of subjects: 34
Study 1984813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 6872413 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg amrinone
Number of subjects: 18
Study 6872413 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg amrinone
Number of subjects: 18
Study 6872413 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg amrinone
Number of subjects: 18
Study 31752954 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI
Number of subjects: 600
Study 31752954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI/US fusion-guided biopsy
Number of subjects: 600
Study 31752954 — intervention group
Group type: COMPARATOR
Intervention: TRUS-only biopsy
Number of subjects: 600
Study 29322972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative lumbar subarachnoid drainage (LSAD)
Number of subjects: 60
Study 29322972 — intervention group
Group type: COMPARATOR
Intervention: No lumbar drain insertion (no LSAD)
Number of subjects: 60
Study 27009515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 'intensive' treatment (complete resolution of IRF and SRF)
Number of subjects: 347
Study 27009515 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 'relaxed' treatment (resolution of IRF or >200 μm SRF only at foveal centre)
Number of subjects: 347
Study 27009515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 'intensive' treatment
Number of subjects: 347
Study 27009515 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 'relaxed' treatment
Number of subjects: 347
Study 26978207 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled xenon combined with hypothermia (33°C) for 24 hours (n=55)
Number of subjects: 110
Study 26978207 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia treatment alone (n=55)
Number of subjects: 110
Study 22433613 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 32
Study 22433613 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus regular moderate aerobic exercise (HDMAE)
Number of subjects: 32
Study 20298591 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg SC enoxaparin
Number of subjects: 72
Study 20298591 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg SC enoxaparin
Number of subjects: 72
Study 20298591 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg SC enoxaparin
Number of subjects: 72
Study 20298591 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg SC enoxaparin
Number of subjects: 72
Study 18534276 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime 0.5 microg/kg/min
Number of subjects: 120
Study 18534276 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime 1.0 microg/kg/min
Number of subjects: 120
Study 18534276 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime 1.5 microg/kg/min
Number of subjects: 120
Study 18534276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15778562 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program (40 minutes, once a week for 6 weeks)
Number of subjects: 22
Study 15778562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 12459658 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflubron emulsion (1.8 g/kg, with an additional 0.9 g/kg dose if hemoglobin < 6.5 g/dl)
Number of subjects: 492
Study 12459658 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflubron emulsion (PFC)
Number of subjects: 492
Study 12459658 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard of care)
Number of subjects: 492
Study 10347103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 10-12 mg/kg/d taken as a single bedtime dose
Number of subjects: 98
Study 10347103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 8551317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at subhypnotic doses
Number of subjects: 32
Study 8551317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1960304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 120
Study 1960304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6443090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine (5 mg dose)
Number of subjects: 23
Study 6443090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine (repeated 5 mg doses)
Number of subjects: 23
Study 6443090 — intervention group
Group type: COMPARATOR
Intervention: Control (no tubocurarine)
Number of subjects: 23
Study 29991076 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee closure in flexion at 90°
Number of subjects: 75
Study 29991076 — intervention group
Group type: COMPARATOR
Intervention: Knee closure in extension
Number of subjects: 75
Study 28629270 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified wheelchair arm-support for at least 60 minutes a day, six days a week, for four weeks
Number of subjects: 120
Study 28629270 — intervention group
Group type: COMPARATOR
Intervention: Basic rehabilitation training and wheelchair assistance
Number of subjects: 120
Study 26692037 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional asthma education
Number of subjects: 88
Study 26692037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional asthma education)
Number of subjects: 88
Study 24531810 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min of leg cycling (noncuffed exercise)
Number of subjects: 21
Study 24531810 — intervention group
Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 21
Study 24531810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed exercise
Number of subjects: 21
Study 24531810 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncuffed exercise
Number of subjects: 21
Study 23285026 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber hand illusion
Number of subjects: 36
Study 23285026 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 20306820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous montelukast, 5.25 mg
Number of subjects: 276
Study 20306820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 21514123 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐29 (bakumondoto) for 2 weeks
Number of subjects: 19
Study 21514123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TJ‐29) for 2 weeks
Number of subjects: 19
Study 21514123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TJ‐29 and control)
Number of subjects: 19
Study 15951475 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite extended-release (ER) capsule (200 mg DP + 25 mg aspirin)
Number of subjects: 20
Study 15951475 — intervention group
Group type: COMPARATOR
Intervention: Conventional dipyridamole tablets (two 100 mg tablets + 81 mg aspirin)
Number of subjects: 20
Study 15951475 — intervention group
Group type: COMPARATOR
Intervention: Conventional dipyridamole tablets (immediate-release)
Number of subjects: 20
Study 11807777 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA heterozygotes (6 BRCA1, 2 BRCA2)
Number of subjects: 8
Study 11807777 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA heterozygotes (8 BRCA1, 1 BRCA2)
Number of subjects: 8
Study 9601159 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive placebo suggestion
Number of subjects: 36
Study 9601159 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative placebo suggestion
Number of subjects: 36
Study 9601159 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 8273981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 324 mg/d
Number of subjects: 16
Study 8273981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1300 mg/d
Number of subjects: 16
Study 8273981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 2600 mg/d
Number of subjects: 16
Study 8273981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 3 mg/d
Number of subjects: 16
Study 8273981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg/d
Number of subjects: 16
Study 8273981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 30 mg/d
Number of subjects: 16
Study 8273981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/d
Number of subjects: 16
Study 8273981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2647014 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar electrocoagulation
Number of subjects: 75
Study 30043934 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 60
Study 30043934 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-pregnant women)
Number of subjects: 60
Study 27789385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo suggestions (suggestions of pain increase with nocebo cream)
Number of subjects: 0
Study 27789385 — intervention group
Group type: COMPARATOR
Intervention: Placebo suggestions (suggestions of pain decrease with placebo cream)
Number of subjects: 0
Study 27789385 — intervention group
Group type: COMPARATOR
Intervention: Natural history group (no treatment)
Number of subjects: 0
Study 27789385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo group (suggestions of pain increase)
Number of subjects: 0
Study 25909846 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM combined with anodal tDCS
Number of subjects: 3
Study 25909846 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM combined with cathodal tDCS
Number of subjects: 3
Study 25909846 — intervention group
Group type: COMPARATOR
Intervention: ABM combined with sham tDCS
Number of subjects: 3
Study 22944550 — intervention group
Group type: EXPERIMENTAL
Intervention: Head positioned with a support
Number of subjects: 60
Study 22944550 — intervention group
Group type: COMPARATOR
Intervention: Head positioned without a support
Number of subjects: 60
Study 19819486 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage and exercise programme
Number of subjects: 66
Study 19819486 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (simulated magnetotherapy)
Number of subjects: 66
Study 17975506 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 (30% v/v)
Number of subjects: 15
Study 17975506 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 (40% v/v)
Number of subjects: 15
Study 17975506 — intervention group
Group type: EXPERIMENTAL
Intervention: ethyl acetate (5.5% v/v)
Number of subjects: 15
Study 17975506 — intervention group
Group type: EXPERIMENTAL
Intervention: ethyl acetate (9.3% v/v)
Number of subjects: 15
Study 17975506 — intervention group
Group type: EXPERIMENTAL
Intervention: acetic acid (205 v/v)
Number of subjects: 15
Study 17975506 — intervention group
Group type: EXPERIMENTAL
Intervention: acetic acid (40 v/v)
Number of subjects: 15
Study 17975506 — intervention group
Group type: COMPARATOR
Intervention: All stimuli
Number of subjects: 15
Study 16875159 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (267 mg/d)
Number of subjects: 35
Study 16875159 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 35
Study 12499050 — intervention group
Group type: EXPERIMENTAL
Intervention: C1r codon 135 polymorphism
Number of subjects: 0
Study 11712441 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet autoantibody occurrence determined by ELISA method
Number of subjects: 15
Study 11712441 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet morphological parameters evaluation
Number of subjects: 15
Study 11712441 — intervention group
Group type: EXPERIMENTAL
Intervention: Megathrombocyte population evaluation
Number of subjects: 15
Study 8829419 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional morphine 5 mg injected in the incision (10 patients)
Number of subjects: 40
Study 8829419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 5 mg (10 patients)
Number of subjects: 40
Study 8829419 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine 5 mg (10 patients)
Number of subjects: 40
Study 8829419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injected in the incision, 10 patients)
Number of subjects: 40
Study 1625092 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) alone
Number of subjects: 70
Study 1625092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hGH plus oxandrolone
Number of subjects: 70
Study 1625092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with hGH (both alone and in combination with oxandrolone)
Number of subjects: 70
Study 6548095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of methohexitone (5 mg/kg)
Number of subjects: 20
Study 6548095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of methohexitone (25 mg/kg)
Number of subjects: 20
Study 6548095 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of methohexitone (2 mg/kg)
Number of subjects: 20
Study 6548095 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pharmacokinetics in children vs adults
Number of subjects: 20
Study 31750210 — intervention group
Group type: EXPERIMENTAL
Intervention: Inj Caroverine
Number of subjects: 86
Study 31750210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba extract
Number of subjects: 86
Study 31750210 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Inj)
Number of subjects: 86
Study 31750210 — intervention group
Group type: COMPARATOR
Intervention: Placebo (extract)
Number of subjects: 86
Study 30316811 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Periodization (LP)
Number of subjects: 36
Study 30316811 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (NLP)
Number of subjects: 36
Study 25888661 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 72) - provided information related to ultrasound findings and allowed to watch the procedures from the monitor
Number of subjects: 151
Study 25888661 — intervention group
Group type: COMPARATOR
Intervention: Group II (n = 79) - received injection only without any collaboration
Number of subjects: 151
Study 25319729 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day aqueous saffron extract orally
Number of subjects: 34
Study 25319729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23007147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 8 mg/m² (day 1) and Vinorelbine (VNR) 25 mg/m² (days 1 and 8) every 4 weeks for up to 6 cycles
Number of subjects: 51
Study 19797535 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan with ciprofloxacin
Number of subjects: 45
Study 19797535 — intervention group
Group type: COMPARATOR
Intervention: Alvimopan without ciprofloxacin
Number of subjects: 45
Study 17445831 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0
Study 17445831 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR 150 mg/day
Number of subjects: 0
Study 15905675 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir (RTV) (300/100 mg or 600/100 mg twice daily, or 900/100 mg once daily)
Number of subjects: 50
Study 15905675 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir (RTV)
Number of subjects: 50
Study 15905675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in PIs)
Number of subjects: 50
Study 12506950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole suspension 3 mg/kg in a single daily dose for 7 days
Number of subjects: 34
Study 12506950 — intervention group
Group type: COMPARATOR
Intervention: Nystatin oral suspension four times a day for 10 days
Number of subjects: 34
Study 9883920 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical termination
Number of subjects: 275
Study 9883920 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical termination
Number of subjects: 275
Study 9883920 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 275
Study 7569503 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2705441 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous DDAVP
Number of subjects: 9
Study 2705441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2705441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous DDAVP
Number of subjects: 9
Study 335794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiazide and methyldopa (regimen A)
Number of subjects: 28
Study 335794 — intervention group
Group type: COMPARATOR
Intervention: Combination of beta-receptor blocker and hydralazine (regimen B)
Number of subjects: 28
Study 30552937 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 181
Study 30552937 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 181
Study 27693959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge orthotics
Number of subjects: 109
Study 27693959 — intervention group
Group type: COMPARATOR
Intervention: Neutral orthotics
Number of subjects: 109
Study 25029662 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000-point group
Number of subjects: 0
Study 25029662 — intervention group
Group type: COMPARATOR
Intervention: 0-point group
Number of subjects: 0
Study 23400616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed JM program (10-15 minutes a day, 5 days a week for 5 weeks)
Number of subjects: 20
Study 21272821 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD intervention
Number of subjects: 137
Study 21272821 — intervention group
Group type: COMPARATOR
Intervention: Control (paper handouts)
Number of subjects: 137
Study 19066876 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance (Shaklee Corp.)
Number of subjects: 19
Study 19066876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatorade
Number of subjects: 19
Study 19066876 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 19
Study 17373593 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced learning trial (P)
Number of subjects: 42
Study 17373593 — intervention group
Group type: COMPARATOR
Intervention: Non-paced control (NP)
Number of subjects: 42
Study 17373593 — intervention group
Group type: EXPERIMENTAL
Intervention: HR feedback
Number of subjects: 42
Study 17373593 — intervention group
Group type: EXPERIMENTAL
Intervention: HR + RPE feedback
Number of subjects: 42
Study 17373593 — intervention group
Group type: EXPERIMENTAL
Intervention: No feedback (CONT)
Number of subjects: 42
Study 15382974 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving Cancer Competently Intervention Program (SCCIP) - a 4-session, 1-day intervention
Number of subjects: 150
Study 15382974 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 150
Study 11441208 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acetaminophen (1000 mg)
Number of subjects: 75
Study 11441208 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetaminophen (500 mg)
Number of subjects: 75
Study 11441208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9097872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 50
Study 9097872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8332152 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment with ceftriaxone (50 mg/kg body weight, initial dose followed by a second dose 24 hours later)
Number of subjects: 86